Diclofenac Potassium

CHEMBL1200804 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
334.2 g/mol
LogP
Phase
4

The potassium salt of diclofenac, a faster-absorbing oral NSAID formulation used for acute pain conditions including primary dysmenorrhea, migraine, and postoperative pain. The potassium salt dissolves more rapidly than the sodium salt.

น้ำหนักโมเลกุล

334.2000 g/mol

TPSA

52.20 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]

InChI

InChI=1S/C14H11Cl2NO2.K/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1

Molecular Formula

C14H10Cl2KNO2

HBD / HBA

1 / 3

พันธะที่หมุนได้

4

อะตอมหนัก

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The potassium salt of diclofenac, a faster-absorbing oral NSAID formulation used for acute pain conditions including primary dysmenorrhea, migraine, and postoperative pain. The potassium salt dissolves more rapidly than the sodium salt.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Diclofenac Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200804. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23667642. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.